Infectious Diseases News and Research

RSS

Embryonic stem cells hold great promise for biomedical science

With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.

14 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

14 Jun 2012

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Today, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children's National Medical Center, began vaccinating participants for a Phase 1 clinical trial of a novel human hookworm vaccine.

14 Jun 2012

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Inovio Pharmaceuticals, Inc. announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.

14 Jun 2012

MDA5 molecule plays a critical role in fighting viral infections

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

HLA B-27 protein appears to confer ability to suppress HIV viral replication

The rare ability of some individuals to control HIV infection with their immune system alone appears to depend - at least partially - on specific qualities of the immune system's killer T cells and not on how many of those cells are produced.

13 Jun 2012

Transgenic mosquitoes can control malaria

Mosquitoes bred to be unable to infect people with the malaria parasite are an attractive approach to helping curb one of the world's most pressing public health issues, according to UC Irvine scientists.

13 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

Trudeau Institute to receive sub-contract for translational research grant from NIH

The Trudeau Institute has announced it is the recipient of a sub-contract for a translational research grant from the National Institutes of Health.

12 Jun 2012

Antibacterial cloths could reduce geriatric MRSA

Using disposable antibacterial cloths to bathe elderly patients reduces the transmission rate of methicillin-resistant Staphylococcus aureus, show Canadian study results.

11 Jun 2012

Polymorphism ’protective in pneumococcal disease’

Patients with invasive pneumococcal disease who have the FcyRIIa-R/R131 polymorphism may have better survival outcomes than those without the genotype, suggest study findings.

11 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Restoration of normal glucose regulation may prevent diabetes

People with pre-diabetes are significantly less likely to develop diabetes if their blood glucose levels are normalized in time, according to new research by the Colorado School of Public Health and the University of Colorado School of Medicine.

11 Jun 2012

CLC bio implements specialized antibody engineering and selection module for Crucell

Today CLC bio announced the completion and final implementation of a specialized antibody engineering and selection module for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio's bioinformatics platform.

11 Jun 2012

Vitamin D deficiency may account for unexplained disparities in cancer survival rates

A paper just published in Dermato-Endocrinology suggests that vitamin D deficiency may account for unexplained disparities in cancer survival rates between African and White Americans.

10 Jun 2012

Project aims to reduce transmission of infectious diseases on aircraft

A new study is expected to provide the first detailed information on how infectious diseases may be transmitted aboard commercial airliners. Sponsored by aircraft manufacturer Boeing, the research will document patterns of passenger movement inside aircraft cabins and inventory the microbes present in cabin air and on surfaces such as tray tables and lavatory fixtures.

8 Jun 2012

Study: HIV superinfection may be more common than previously believed

Human immunodeficiency virus (HIV) superinfection may be as common as initial HIV infection and is not limited to high risk-populations, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases.

8 Jun 2012

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

JDRF and BD today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information.

From BD (Becton, Dickinson and Company) 8 Jun 2012